TITLE

Hemispherx Biopharma expands SARS initiative

PUB. DATE
December 2003
SOURCE
PharmaWatch: Biotechnology;December 2003, Vol. 2 Issue 12, p9
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
Introduces new drug delivery formats of Alferon N and Ampligen, lead compounds developed by Hemispherx Biopharma Inc. Clinical indications of the drugs; Description of Alferon N and Ampligen; Presentation of the clinical trial of the drugs.
ACCESSION #
13840386

 

Related Articles

  • Independent study shows Ampligen superior to other antivirals.  // PharmaWatch: Biotechnology;August 2003, Vol. 2 Issue 8, p6 

    Focuses on the research on Ampligen, an antiviral agent and important investigational immunotherapeutic under development by Hemispherx Biopharma Inc. Presentation of the clinical study of Ampligen; Superiority of Ampligen over other antivirals; Indications for Ampligen.

  • Chronic tonic.  // Pharmaceutical Executive;May98, Vol. 18 Issue 5, p134 

    Announces a Phase III clinical study of Hemispherx Biopharma's clinical study of its drug Ampligen. Details on the placebo-controlled study; Results of earlier trial.

  • Successful phase II efficacy results with NicOx compound in acute pain.  // PharmaWatch: Biotechnology;August 2003, Vol. 2 Issue 8, p10 

    Reports on the result of the clinical trial of NCX 701 by NicOx SA for pain management. Efficacy of NCX 701 to treat acute pain; Patients enrolled in the clinical study; Presentation of the clinical study of NCX 701.

  • New data highlight Aranesp efficacy in anemic patients with lymphoid cancer.  // PharmaWatch: Biotechnology;August 2003, Vol. 2 Issue 8, p10 

    Reports on the presentation of a data on the efficacy of Amgen Inc.'s Aranesp, a therapeutic agent for anemic patients with lymphoid cancer. Presentation of the clinical trial of Aranesp; Efficacy of Aranesp in treating anemia; Patients enrolled in the study.

  • IRC initiates preclinical development program for HIV vaccine candidate.  // PharmaWatch: Biotechnology;December 2003, Vol. 2 Issue 12, p6 

    Reports that the Immune Response Corp. has initiated a preclinical development program with IR103, a new vaccine candidate for the prevention and treatment of HIV. Presentation of the clinical study of IR103; Potentiality of IR103 to prevent and treat HIV; Effect of IR103 on immune response.

  • Genaera's preclinical research finds squalamine to be an effective anti-angiogenic.  // PharmaWatch: Biotechnology;December 2003, Vol. 2 Issue 12, p7 

    Reports on the result of the clinical study of squalimine, an anti angiogenic compound developed by Genaera Corp. Presentation of the clinical trial of squalimine; Efficacy of squalimine to block rapid vascular growth factor; Description and characteristics of squalimine.

  • Esperion's ETC-216 proves effective in reversing atherosclerosis.  // PharmaWatch: Biotechnology;December 2003, Vol. 2 Issue 12, p8 

    Reports on the result of the clinical study on ETC-216, a drug candidate developed by Esperion Therapeutics. Presentation of the clinical study of ETC-216; Description of ETC-216; Patients enrolled in the study.

  • Dendreon's prostate cancer trials indicate Provenge as effective treatment.  // PharmaWatch: Biotechnology;December 2003, Vol. 2 Issue 12, p8 

    Presents data from the clinical trial of Provenge, a drug candidate developed by Dendreon Corp. for the treatment of androgen independent prostate cancer. Presentation of the clinical trial of Provenge; Patients enrolled in the study; Potentiality of Provenge in treating prostate cancer.

  • VaxGen HIV vaccine trial fails to meet endpoints.  // PharmaWatch: Biotechnology;December 2003, Vol. 2 Issue 12, p9 

    Focuses on the study of Aidsvax, an investigational vaccine for the prevention of HIV infection under development by VaxGen Inc. Presentation of the clinical trial of Aidsvax; Evaluation of the potentiality of the vaccine candidate; Analysis of the trial results on Aidsvax.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics